Phenotypic and molecular methods for detecting carbapenem-hydrolyzing enzymes in Gram-negative bacteria
Detection of carbapenemase-producing organisms (CPOs) begins with routine antimicrobial susceptibility testing (AST). Automated broth microdilution systems (Vitek 2, MicroScan, Phoenix) or manual disk diffusion flag any Enterobacterales, Pseudomonas aeruginosa, or Acinetobacter baumannii isolate with elevated meropenem, imipenem, or ertapenem MICs. CLSI M100 and CDC laboratory protocols specify that any isolate meeting screening criteria must reflex to a confirmatory phenotypic carbapenemase test before a final susceptibility report is released — because carbapenem resistance can arise from carbapenemases, but also from porin loss plus AmpC/ESBL, which carries very different infection-control implications.
Elevated carbapenem MICs can result from two fundamentally different mechanisms:
• Carbapenemase production — an enzyme that hydrolyzes the carbapenem ring directly. Highly transmissible via plasmids, associated with outbreaks, requires contact precautions. • Non-carbapenemase mechanisms — porin (OmpK35/36) loss combined with AmpC overexpression or ESBL production. Reduces carbapenem susceptibility without a transferable carbapenemase gene; lower (though non-zero) transmission risk.
Because the infection-control and public-health response differs enormously between these two categories, CLSI and CDC algorithms mandate reflex confirmatory testing (mCIM, and increasingly molecular assays) for any isolate crossing the screening breakpoint, rather than relying on the screening MIC alone.
Carbapenem-resistant Enterobacterales (CRE) remain one of only a handful of pathogens on the CDC "urgent threat" tier — the highest hazard category — reflecting both high transmissibility and limited remaining treatment options.
Once a screening result is flagged, US laboratories most commonly proceed to the modified carbapenem inactivation method (mCIM), which replaced the older Modified Hodge Test (MHT) in CLSI guidance in 2017 because MHT produced unacceptable false-positive rates with AmpC/porin-loss isolates and could not detect some OXA-48-like producers reliably. Many high-volume laboratories now run mCIM in parallel with, or are transitioning entirely to, rapid molecular assays that bypass phenotypic confirmation altogether for the most urgent specimen types (e.g., blood cultures).
The confirmatory carbapenemase algorithm applies broadly across Enterobacterales (Klebsiella pneumoniae, Escherichia coli, Enterobacter cloacae complex, Citrobacter freundii, Serratia marcescens are the most frequently implicated species) and, with modified interpretive criteria, to Pseudomonas aeruginosa and Acinetobacter baumannii. Reflex testing is performed regardless of specimen source — urine, respiratory, wound, or blood — but blood culture isolates and isolates from patients being transferred between facilities receive the highest testing priority because of the direct link between recognition speed and both individual mortality risk and onward transmission risk.
The mCIM is a functional (phenotypic) assay: rather than detecting a gene or protein directly, it detects the biochemical consequence of carbapenemase activity — destruction of a meropenem disk's potency. A 1-µL loopful of the test organism is emulsified in 2 mL of tryptic soy broth (TSB) to a heavy suspension, a standard 10-µg meropenem disk is submerged in the broth, and the tube is incubated at 35±2°C in ambient air for exactly 4 hours ± 15 minutes. During this window, any carbapenemase secreted or released by lysing cells diffuses into the disk matrix and progressively degrades the meropenem reservoir.
Step-by-step mCIM setup:
1. Prepare a heavy bacterial suspension: emulsify a 1-µL loopful of pure overnight growth in 2 mL TSB (roughly equivalent to a 0.5–McFarland-and-above turbid suspension — deliberately denser than standard AST inocula to maximize enzyme yield). 2. Vortex thoroughly to disperse clumps and standardize contact between organism and disk. 3. Add one standard 10-µg meropenem disk to the tube, ensuring it is fully submerged. 4. Incubate at 35±2°C in ambient air (not CO2) for 4 hours ± 15 minutes — timing precision matters because under-incubation reduces sensitivity and over-incubation can allow even weak or slow carbapenemases to falsely register as negative-strain inactivation artifacts. 5. Remove the disk with sterile forceps and transfer it directly onto a fresh Mueller-Hinton agar plate pre-swabbed with the indicator strain (Stage 3).
Unlike molecular tests, mCIM detects functional enzymatic activity regardless of the specific resistance gene — meaning it will flag carbapenemases not yet covered by any commercial multiplex PCR panel, at the cost of a same-day-plus-overnight turnaround instead of PCR's ~1 hour.
A parallel tube containing EDTA (a divalent-cation chelator) can be run alongside the standard mCIM. Metallo-beta-lactamases (NDM, VIM, IMP) require zinc ions in their active site to hydrolyze carbapenems; EDTA strips this zinc and abolishes their activity, restoring a normal zone on the indicator lawn. Serine carbapenemases (KPC, OXA-48-like) are zinc-independent and remain fully active despite EDTA. A positive mCIM combined with a positive eCIM (zone restored with EDTA) strongly suggests an MBL, informing empiric therapy choices before PCR results return.
Because mCIM requires a discrete 4-hour broth incubation followed by an 18–24 hour agar incubation, the assay typically spans a full laboratory shift plus overnight — meaning a specimen collected in the morning will not yield a final mCIM result until the following day at the earliest. Laboratories batch mCIM setups to align with standard AST reading times, and many now run a rapid molecular test in parallel for high-acuity specimens (bloodstream isolates, ICU patients) so that antimicrobial therapy is not delayed waiting on the slower phenotypic confirmation, while still using mCIM as the authoritative confirmatory method for the medical record and infection-control determination.
The pre-incubated meropenem disk is placed onto a Mueller-Hinton agar plate freshly lawned with a 0.5 McFarland suspension of carbapenem-susceptible indicator E. coli ATCC 25922. The plate is incubated 18–24 hours at 35°C in ambient air, then the zone of inhibition around the disk is measured in millimeters, exactly as in standard disk-diffusion susceptibility testing — except here the "susceptibility" being measured is the reference strain's, not the test isolate's.
The logic of mCIM is inverted relative to standard susceptibility testing: a SMALL or absent zone is the abnormal, clinically alarming result. If the test organism produced carbapenemase during the broth incubation step, the meropenem in the disk was destroyed before it ever reached the indicator lawn — so the drug cannot diffuse outward and inhibit the susceptible E. coli, and growth crowds right up to the disk edge (zone ≤15 mm = positive). If no carbapenemase was produced, the disk retains its potency, diffuses normally into the agar, and produces a large, clean zone of inhibition around the disk (≥19 mm = negative), just as it would in a conventional susceptibility test.
Zones falling in the 16–18 mm indeterminate range should prompt repeat testing, as they may reflect weak carbapenemase activity, inoculum variability, or borderline non-enzymatic resistance mechanisms.
Reliable mCIM zone reading requires strict adherence to timing and inoculum density at every step. Common sources of error include: under-dense bacterial suspension in the broth step (falsely large zone / false negative), over-incubation of the broth step allowing weak enzymes extra time to act (potential false positive), and indicator lawn density outside the 0.5 McFarland target (shifts zone diameters unpredictably). Laboratories run ATCC quality-control strains with known carbapenemase status (e.g., a KPC-positive control and a susceptible negative control) with each batch to verify the assay is performing within expected ranges before releasing patient results.
A zone-diameter measurement confirms that a carbapenemase is present but reveals nothing about which gene family is responsible, nor whether the isolate carries more than one carbapenemase simultaneously (co-production of KPC and NDM has been documented in outbreak strains and confers even broader resistance). Weak or slow-hydrolyzing enzymes, particularly some OXA-48-like variants, can occasionally produce indeterminate or borderline-negative zones despite genuine carbapenemase activity, which is why any strongly resistant isolate with a negative or indeterminate mCIM in the face of a very high carbapenem MIC should still prompt molecular testing rather than being dismissed as carbapenemase-negative.
A positive phenotypic screen (mCIM) confirms that a carbapenemase is present but does not identify which one. Molecular methods — multiplex real-time PCR panels (e.g., Xpert Carba-R, BioFire) or antigen-based lateral-flow immunoassays (e.g., NG-Test CARBA 5) — detect and distinguish the five major carbapenemase gene/protein families: KPC, NDM, VIM, IMP, and OXA-48-like. This distinction is not academic: each family has a different geographic epidemiology, a different hydrolytic mechanism, and critically different susceptibility to novel beta-lactam/beta-lactamase-inhibitor combinations, directly shaping empiric and definitive antibiotic selection.
• KPC (Klebsiella pneumoniae carbapenemase) — Class A serine carbapenemase; predominant in the United States, Italy, Greece, China, Colombia, and Israel; historically the leading cause of CRE in North America. • NDM (New Delhi metallo-beta-lactamase) — Class B metallo-enzyme; endemic on the Indian subcontinent, spreading through the Balkans, Middle East, and increasingly detected worldwide via medical tourism and international travel. • VIM / IMP (Verona integron-encoded / imipenemase metallo-beta-lactamases) — Class B metallo-enzymes; concentrated in Mediterranean Europe (Greece, Italy) and parts of East Asia including Japan. • OXA-48-like — Class D serine carbapenemase; widespread across Turkey, North Africa, the Middle East, and the Indian subcontinent, notable for weak/variable carbapenem MIC elevation that can be missed by screening if breakpoints are applied too permissively.
Serine carbapenemases (KPC, OXA-48-like) are inhibited by avibactam, relebactam, and vaborbactam — meaning ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam remain active options. Metallo-beta-lactamases (NDM, VIM, IMP) use a zinc-dependent mechanism that none of these novel inhibitors block, rendering ceftazidime-avibactam alone ineffective against MBL producers. For MBL infections, clinicians must turn to aztreonam-avibactam (aztreonam evades MBL hydrolysis but is often degraded by co-produced ESBLs, which avibactam then rescues) or cefiderocol, a siderophore cephalosporin that uses iron-transport channels to bypass many resistance mechanisms.
Molecular gene identification is the single most decision-relevant data point in CPO management — it is the fork in the road between "ceftazidime-avibactam will likely work" and "you need aztreonam-avibactam or cefiderocol."
Multiplex real-time PCR platforms (Xpert Carba-R, BioFire panels) amplify carbapenemase gene targets directly from isolated colonies or, for some platforms, directly from positive blood culture broth, returning results in under an hour with sensitivity and specificity generally exceeding 95–98% for the targeted gene families. Lateral-flow immunoassays (NG-Test CARBA 5) instead detect the carbapenemase protein itself using family-specific monoclonal antibodies, require no thermal cycler, and return a visual result in about 15 minutes from a bacterial colony suspension — making them attractive for smaller laboratories or rapid bedside-adjacent triage, at the cost of only detecting the five antibody-targeted protein families rather than any hydrolysis-capable variant.
A confirmed carbapenemase-producing organism triggers an institutional and public-health response disproportionate to almost any other AST result. CPO bloodstream infections carry crude mortality rates approaching 40–50% in published cohorts (higher for NDM and pan-drug-resistant strains), and plasmid-borne carbapenemase genes spread readily between species and institutions. Confirmed cases prompt immediate contact precautions, cohorting or single-room placement, active surveillance cultures of roommates and unit contacts, environmental cleaning review, and mandatory notification of hospital infection prevention teams and, in most US states, public health departments.
CDC's national CPO containment strategy rests on three pillars: (1) rapid detection through mandated phenotypic/molecular confirmatory testing as described in prior stages, (2) immediate implementation of contact precautions and, where available, single-patient rooms for the duration of hospitalization, and (3) an aggressive response team that performs point-prevalence active surveillance cultures on roommates, other patients cared for by the same staff, and sometimes an entire unit, to identify silent colonization before it becomes a transmission chain. Isolates and case data are reported to state and local health departments, which coordinate inter-facility communication — critical because patients are frequently transferred between acute care, long-term acute care, and skilled nursing facilities, each a potential amplification point.
Three features distinguish CPOs from most other multidrug-resistant organisms and justify the intensity of the response: high plasmid transmissibility (the resistance gene itself, not just the strain, can spread to unrelated species), a shrinking antibiotic pipeline (only a handful of agents — ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, cefiderocol, aztreonam-avibactam — retain reliable activity, and none are universally active against all five gene families), and documented healthcare-associated outbreaks with population-level mortality impact, including well-characterized US regional KPC outbreaks and international NDM spread linked to medical tourism.
Because no single novel agent covers all carbapenemase families, molecular identification (Stage 4) is not just diagnostically satisfying — it directly determines whether empiric therapy has any chance of covering the isolate, making the full detection pipeline a genuine matter of life and death.
CPO status must travel with the patient: electronic medical record flags, verbal handoff at transfer, and formal notification to receiving facilities are all required components of a complete infection-control response, because a missed handoff is one of the most common root causes of unrecognized CPO transmission between institutions. Many jurisdictions also require reporting of CPO cases to state health departments as part of reportable-disease surveillance, feeding regional and national data (including CDC's National Healthcare Safety Network) used to track emerging resistance trends and target containment resources toward facilities and regions experiencing clusters.